A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00556712 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

889

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: erlotinib [Tarceva]
DRUG: Placebo

Sponsor

Hoffmann-La Roche